Adrenocorticotropic Hormone [ACTH] Market Size Report, 2022-2030
The global Adrenocorticotropic Hormone [ACTH] market gathered revenue around USD 2.1 billion in 2021 and market is set to grow USD 4.7 billion by the end of 2030 and is estimated to expand at a modest CAGR of 3.7% during the prediction period 2022 to 2030.
Need for the development of newer and technologically enhanced products is rising globally, owing to treatment efficiency of drugs. Hence, major players operating in the market invest in research & development in order to develop new drugs. The rise in investments in research & development by key players is anticipated to propel the global adrenocorticotropic hormone (ACTH) market.
Report Scope of the Adrenocorticotropic Hormone [ACTH] Market
|
Report Coverage |
Details |
|
Market Size |
US$ 4.7 Billion by 2030 |
|
Growth Rate |
CAGR of 3.7% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Source, Indication, Distribution Channel and Region, |
|
Companies Mentioned |
Mallinckrodt plc, Pfizer, Inc., Novartis AG, Merck KGaA, Ferring B.V., Avantor, Inc., Viatris, Inc., and Hikma Pharmaceuticals plc. |
Multiple Applications, Rise in Prevalence of Chronic Diseases to Drive Global Market
H.P. Acthar Gel was Questcor Pharmaceuticals, Inc.'s primary corticotropin product, which was acquired by Mallinckrodt in August 2014. The U.S. FDA approved Acthar for the treatment of 19 indications. The rate of infantile spasm is estimated to be 2.5 to 6.0 per 10,000 live births. Its prevalence rate is 1.5 to 2.0 per 10,000 children aged 10 years or younger, based on data published in the National Organization for Rare Disorders, Inc. According to the Centers for Disease Control and Prevention (CDC), about 23% adults in the U.S., which is more than 54 million people, have arthritis. The disease is expected to affect 78 million adults in the country by 2040.
According to data published in the National Center for Biotechnology Information in 2019, the estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 people, and approximately 1.2 million to 1.9 million people are at risk per year.
Adrenocorticotropic hormone (ACTH) has re-emerged as a treatment for proteinuria due to nephrotic syndrome (NS) in the last decade. Nephrotic syndrome is one of the most common chronic renal diseases in children. It has an incidence of 2 to 7 per 100,000 and a prevalence of 16 per 100,000, well above the 1 per 1 million incidence of chronic renal failure in children. Hence, rise in cases of target diseases and applications of corticotropin in various indications boost the growth of the global market.
Natural Source to Dominate Global Market
In terms of source, the global adrenocorticotropic hormone (ACTH) market has been bifurcated into natural and synthetic. The natural segment dominated the global adrenocorticotropic hormone (ACTH) market in 2020, and the trend is projected to continue during the forecast period.
Rheumatology to Gain Market Share, Offer Lucrative Opportunities
Based on indication, the global market has been classified into rheumatology, neurology, nephrotic syndrome, ophthalmology, and others. Arthritis is a chronic autoimmune disorder that causes flare up, stiffness, and swelling in the joints, especially in the lower extremities. Common types of arthritis are osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and gout. Arthritis is a wide term covering around 100 types of joint diseases. Several patients with psoriasis develop arthritis. All these factors are expected to drive the rheumatology segment.
Hospital Pharmacies to be Highly Lucrative Distribution Channel
Based on distribution channel, the global adrenocorticotropic hormone (ACTH) market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global adrenocorticotropic hormone (ACTH) market, and the trend is anticipated to continue during the forecast period. The rise in the adoption of e-commerce is anticipated to propel the online pharmacies segment in the near future.
North America to Lead Adrenocorticotropic Hormone (ACTH) Market
North America dominated the global adrenocorticotropic hormone (ACTH) market in 2020 and the trend is likely to continue during the forecast period. The dominance of North America in the global market can be attributed to high rate of adoption of Acthar Gel in a number of indications as well as high cost of the drug in the region.
The market in Europe is projected to expand at a CAGR of 6.98 from 2022 to 2030. Increase in awareness about various diseases, favorable medical reimbursement policies, availability of synthetic ACTH (tetracosactide), and well-established healthcare facilities are the major factors anticipated to drive the market in Europe during the forecast period.
Some of the prominent players in the Adrenocorticotropic Hormone [ACTH] Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global Adrenocorticotropic Hormone (ACTH) Market: Segmentation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Adrenocorticotropic Hormone [ACTH] Market Study:
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers